Tokai Pharma (TKAI) Reports Q2 Loss Per Share of $0.40
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Tokai Pharmaceuticals Reports Second Quarter 2015 Results
August 12, 2015 4:00 PM EDTPivotal Phase 3 Trial of Galeterone in AR-V7 Positive Metastatic Castration-Resistant Prostate Cancer on Track for Topline Data by End of 2016
BOSTON--(BUSINESS WIRE)-- Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing proprietary therapies for prostate cancer and other hormonally driven diseases, today reported results for the quarter ended June 30, 2015.
Tokais business highlights for the quarter include the initiation of ARMOR3-SV, Tokais pivotal Phase 3 clinical trial of galeterone in men with metastatic castration-resistant prostate cancer (mCRPC) whose tumor cells express... More
